FDA's RCT demand clashes with Huntington's ethics
The host argued that the FDA's push for a randomized controlled trial (RCT) with a long-term sham arm for UniQure's Huntington's therapy creates an ethical dilemma, as placebo patients would progress to a point where they could never receive the potentially life-altering drug.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.